Research programme: osteoporosis therapy - Tanox/ Wyeth
Alternative Names: Anti secreted apoptosis-related protein 2 monoclonal antibody; Anti-SARP2 humanised monoclonal antibody; Humanised anti-SARP2 monoclonal antibody; TNX-717Latest Information Update: 12 Mar 2008
At a glance
- Originator Tanox; Wyeth
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Apoptosis inhibitors; Osteoblast stimulants; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Fracture; Osteoporosis
Most Recent Events
- 03 Aug 2007 Tanox has been acquired by Genentech
- 04 May 2007 Preclinical development is ongoing
- 12 Jan 2005 Preclinical trials in Fracture treatment in USA (Parenteral)